Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$178.85
+1.3%
$176.47
$136.99
$182.38
$19.75B0.49991,650 shs436,517 shs
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$52.82
-1.9%
$53.73
$39.97
$72.83
$10.07B0.952.58 million shs1.67 million shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$5.60
-0.5%
$5.09
$3.81
$29.30
$516.19M1.911.26 million shs463,756 shs
Natera, Inc. stock logo
NTRA
Natera
$161.50
0.0%
$160.34
$92.14
$183.00
$22.09B1.731.43 million shs468,868 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.00%+0.63%+3.00%+9.00%+26.93%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.00%-1.56%-2.88%+24.12%+22.29%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.00%+6.67%+13.82%-31.12%-77.56%
Natera, Inc. stock logo
NTRA
Natera
0.00%-3.85%-2.42%+20.64%+44.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
4.9386 of 5 stars
2.34.04.24.72.92.52.5
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
4.9409 of 5 stars
4.55.00.04.73.42.50.6
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
4.1562 of 5 stars
4.13.00.04.10.01.70.6
Natera, Inc. stock logo
NTRA
Natera
2.1396 of 5 stars
2.52.00.00.03.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
2.69
Moderate Buy$185.733.85% Upside
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
2.95
Moderate Buy$70.4033.30% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.13
Hold$14.38156.87% Upside
Natera, Inc. stock logo
NTRA
Natera
3.00
Buy$184.6314.32% Upside

Current Analyst Ratings Breakdown

Latest MYGN, DGX, EXAS, and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.00
5/21/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00
5/15/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.00
5/15/2025
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$211.00 ➝ $218.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00
5/8/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$18.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $8.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$10.16B1.97$13.65 per share13.10$61.38 per share2.91
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$2.83B3.52$5.57 per share9.48$12.98 per share4.07
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$837.60M0.62$1.00 per share5.60$7.70 per share0.73
Natera, Inc. stock logo
NTRA
Natera
$1.70B13.00N/AN/A$9.05 per share17.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$871M$7.9122.6117.052.478.81%15.11%6.65%7/22/2025 (Estimated)
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$1.03B-$5.51N/A105.6311.39-36.06%-3.75%-1.68%7/30/2025 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)

Latest MYGN, DGX, EXAS, and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$0.04N/AN/AN/A$774.43 millionN/A
7/22/2025Q2 2025
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.56N/AN/AN/A$2.73 billionN/A
5/8/2025Q1 2025
Natera, Inc. stock logo
NTRA
Natera
-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million
5/6/2025Q1 2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million
5/1/2025Q1 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million
4/22/2025Q1 2025
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.15$2.21+$0.06$1.94$2.63 billion$2.65 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$3.201.79%N/A40.46%14 Years
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A

Latest MYGN, DGX, EXAS, and NTRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2025
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
quarterly$0.801.86%7/7/20257/7/20257/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.84
1.44
1.31
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.97
2.73
2.38
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.08
1.90
1.71
Natera, Inc. stock logo
NTRA
Natera
N/A
3.87
3.74

Institutional Ownership

CompanyInstitutional Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
88.06%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
88.82%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
8.16%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.20%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.40%
Natera, Inc. stock logo
NTRA
Natera
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
56,000111.64 million102.53 millionOptionable
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
7,000188.64 million186.37 millionOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70092.18 million89.97 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
4,434136.55 million126.17 millionOptionable

Recent News About These Companies

Should You Invest in Natera (NTRA)?
Natera, Inc. (NASDAQ:NTRA) Insider Sells $500,310.00 in Stock
Natera, Inc. (NASDAQ:NTRA) Shares Sold by KBC Group NV

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Quest Diagnostics stock logo

Quest Diagnostics NYSE:DGX

$178.85 +2.25 (+1.27%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$177.79 -1.06 (-0.59%)
As of 07/3/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

$52.82 -1.05 (-1.94%)
Closing price 07/3/2025 03:12 PM Eastern
Extended Trading
$52.82 0.00 (0.00%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$5.60 -0.03 (-0.53%)
Closing price 07/3/2025 02:38 PM Eastern
Extended Trading
$5.60 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Natera stock logo

Natera NASDAQ:NTRA

$161.50 -0.07 (-0.04%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$161.50 0.00 (0.00%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.